N/A
N=225
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT00590005 ↗Enrolled (actual)
225
Serious AEs
0.0%
Results posted
Jan 2014
Primary outcome: Primary: Exhaled Nitric Oxide at Baseline and Over the Observational Period — 15.1; 9.9; 13.7; 8.6 parts per billion
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult · 6+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- Jun 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Exhaled Nitric Oxide at Baseline and Over the Observational Period |
15.1; 9.9; 13.7; 8.6 | — |
| SECONDARY Reduction in Breath pH |
7.08; 7.58; 7.68; 7.63 | — |
Summary
Hypotheses: 1) Airway pH regulation is abnormal in severe asthma; 2) In severe asthma, there is formation of cytotoxic nitrogen oxides and loss of beneficial nitrogen oxides in the airways
Eligibility Criteria
Inclusion Criteria
- At least 6 years old
- Asthma diagnosis by physician
- Current treatment with an inhaled corticosteroid medication
Exclusion criteria
- Bronchiectasis
- Cystic Fibrosis
- Chronic Obstructive Pulmonary Disease
Data sourced from ClinicalTrials.gov (NCT00590005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.